Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 18/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411240 | 0.88 | ALDH1A1 (0.45) | CCR5MMP1MMP9MMP13ADAM17 | |
| SCHEMBL6409366 | 0.88 | HSD11B1 (0.40) | CCR5MMP1MMP9MMP13ADAM17 | |
| SCHEMBL6409109 | 0.88 | CCR2 (0.49) | CCR2CCR5 | |
| SCHEMBL6418522 | 0.88 | CCR5 (0.48) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL6408602 | 0.87 | CCR5 (0.47) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL6412802 | 0.87 | CCR2 (0.48) | CCR2CCR5 | |
| SCHEMBL6411432 | 0.87 | CCR2 (0.50) | CCR2CCR5 | |
| SCHEMBL6417579 | 0.86 | CCR2 (0.46) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL6415620 | 0.86 | CCR2 (0.49) | CCR2CCR5 | |
| SCHEMBL6415582 | 0.86 | CCR2 (0.47) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR2 5/4885CCR5 4/4885MMP1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.